ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Feasibility of Fasting While Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00757094
Recruitment Status : Completed
First Posted : September 22, 2008
Last Update Posted : February 25, 2010
Sponsor:
Information provided by:
King Fahad Medical City

Brief Summary:
Fasting (refraining from eating and drinking) during the day is safe while receiving chemotherapy.

Condition or disease
Fasting Chemotherapy Cancer

Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Safety and Feasibility of Fasting While Receiving Chemotherapy
Study Start Date : September 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : March 2009

Group/Cohort
I
Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan



Primary Outcome Measures :
  1. Safety of fasting while receiving chemotherapy [ Time Frame: two months ]

Secondary Outcome Measures :
  1. Effect of fasting on chemotherapy side effects [ Time Frame: two months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Fasting patients who are schedulled to receive chemotherapy during the month of Ramadan
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Established diagnosis of cancer
  • Signed informed consent
  • Adequate CBC and chemistry to receive chemotherapy

Exclusion Criteria:

  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757094


Locations
Saudi Arabia
King Fahad Medical City
Riyadh, Saudi Arabia, 11525
Sponsors and Collaborators
King Fahad Medical City
Investigators
Principal Investigator: Ali SM Al-Shanqeeti, MD King Fahad Medical City